BioSpace News Archive

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that data on its program for the treatment of children with maralixibat will be featured in the late breaking oral presentation session during the American Association for the Study of Liver Diseases Annual Meeting (The Liver Meeting), November 8-12, 2019, in Boston.

SCAN Health Plan®, one of the nation’s largest not-for-profit Medicare Advantage plans, has earned a 4.5-star rating* on a five-point scale from the Centers for Medicare and Medicaid Services (CMS) for the third consecutive year.

On Monday, Humana and Microsoft Corp. announced a strategic partnership focused on building modern health care solutions for Humana members aimed at improving their health outcomes and making their health care experiences simpler to navigate.

For biological researchers looking to reduce their reliance on cold storage without disrupting their existing workflow, Thermo Fisher Scientific’s new cell culture media are the first to remain stable at room temperature.

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced that it will be initiating part 2 of the COURAGE study, an international phase 3 trial to evaluate the safety and efficacy of vibegron for the treatment of symptoms of overactive bladder (OAB) in men with benign prostatic hyperplasia (BPH).

Exagen Inc. announced that the Lupus Foundation of America will be recognizing their CEO Ron Rocca at the upcoming Evening of Hope Gala October 28.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new two-year data from the long-term extension of the Phase 3 UNIFI study. The data demonstrated that the majority of adult patients with moderately to severely active ulcerative colitis who achieved symptomatic remission1 with STELARA® (ustekinumab) were able to sustain remission through week 92.

ANS-6637, which is in Phase 2 clinical development, is a new chemical entity selective ALDH2 Inhibitor with a mechanism of action expected to prevent craving and relapse for patients being treated for substance use disorders.

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of preclinical data that support its investigational gene therapy programs for the treatment of metachromatic leukodystrophy (MLD) and phenylketonuria (PKU) at the American Society of Human Genetics (ASHG) 2019 Meeting.

Veritas Health Innovation Ltd is pleased to announce that it has received grant funding of AU$2,000,000 to support its mission to bring research into practice faster than ever before.